araag2/HINT huggingface dataset:
Clinical trial NCT02029157 (phase 3, status: completed)
Conditions: liver cancer
ICD codes: D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6
Drugs: arq197, placebo
SMILES: O=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent form

          -  ≥20 years old

          -  Inoperable HCC which is not eligible for locoregional therapy

          -  Diagnosed as c-Met high in tumor sample

          -  Radiographic progression is confirmed during or after systemic chemotherapy including
             sorafenib, or those who are intolerance to the chemotherapy.

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1

          -  Child-Pugh Class A

          -  Having measurable target lesions which are defined by Response Evaluation Criteria in
             Solid Tumors (RECIST) version 1.1,

          -  Negative pregnancy test results

          -  Adequate organ function

          -  Life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  More than 2 prior systemic chemotherapy.

          -  Prior therapy of c-Met inhibitor (including antibody)

          -  Any systemic therapy within ≤2 weeks prior to the randomization

          -  Locoregional therapy within ≤4 weeks prior to randomization.

          -  Major surgery within ≤4 weeks prior to the randomization

          -  Concurrent cancer within ≤5 years prior to the randomization

          -  History of cardiac diseases

          -  Active clinically serious infections defined as ≥ Grade 3 according to Common Toxicity
             Criteria for Adverse Effects (CTCAE) 4.0

          -  Any psychological disorder affecting Informed Consent

          -  Diagnosis positive for anti-HIV antibody and/or anti-HTLV-1 antibody

          -  Blood or albumin transfusion within ≤14 days prior to the screening test

          -  Concurrent interferon therapy against Hepatitis B Virus (HBV)/ Hepatitis C Virus (HCV)

          -  Symptomatic brain metastases

          -  History of liver transplantation

          -  Inability to swallow oral medications

          -  Confirmed interstitial lung disease

          -  Pleural effusion and/or clinically significant ascites

          -  Pregnancy or breast-feeding

          -  Without consent to effective single or combined contraceptive methods
Clinical trial NCT02030600 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
        consent - Subjects fulfilling at least one of the below criteria: a) Experienced at least
        one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes
        Association) definition, April 2013), b) Moderate chronic renal failure, defined as
        glomerular filtration rate 30 - 59 mL/min/1.73 m^2 per CKD-Epi (Chronic Kidney Disease
        Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom
        unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of
        hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose
        measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12
        weeks prior to Visit 1 (screening) - Type 2 diabetes mellitus (diagnosed clinically) for at
        least 26 weeks prior to Visit 1 - Current treatment with any basal insulin (OD or BID) ±
        any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor,
        thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 For
        subjects on BID the total daily dose should be below 75 units - HbA1c (glycosylated
        haemoglobin) below or equal to 9.5 % by central laboratory analysis - BMI (body mass index)
        below or equal to 45 kg/m^2 Exclusion Criteria: - Treatment with a bolus insulin separately
        or contained in an insulin mix product within the last 26 weeks prior to Visit 1 - Use of
        any other anti-diabetic agent(s) than those stated in the inclusion criteria within the
        last 26 weeks prior to Visit 1
Clinical trial NCT02032277 (phase 3, status: completed)
Conditions: triple negative breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cyclophosphamide, placebo, doxorubicin, paclitaxel, carboplatin, veliparib, placebo
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, C[C@@]1(CCCN1)C1=NC2=CC=CC(C(N)=O)=C2N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer by core needle or incisional biopsy
             (excisional biopsy is not allowed). Clinical stage T2-3 N0-2 or T1 N1-2 by physical
             exam or radiologic studies.

          2. Documented Breast Cancer Gene (BRCA) germline mutation testing.

          3. Estrogen Receptor (ER)-, Progesterone Receptor (PR)-, and Human Epidermal Growth
             Factor Receptor (HER)2-negative (triple-negative) cancer of the breast.

          4. ECOG Performance status of 0 to 1.

          5. Women must be determined to be not of childbearing potential (surgically sterile, or
             postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR
             they must have a negative serum pregnancy test prior to randomization.

        Exclusion Criteria:

          1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic
             therapy radiotherapy or investigational agents) with therapeutic intent for current
             breast cancer.

          2. Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a
             Poly-(ADP-ribose)-Polymerase (PARP) inhibitor.

          3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal
             agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator
             (SERM). Subjects must have discontinued use of such agents prior to beginning study
             treatment.

          4. A history of seizure within 12 months prior to study entry.

          5. Pre-existing neuropathy from any cause in excess of Grade 1.
Clinical trial NCT02032875 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, sofosbuvir, ribavirin
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Participants must be able to understand and agree to comply with the prescribed dosing
             regimens and procedures, report for regularly scheduled study visits, and reliably
             communicate with study personnel about adverse events and concomitant medications

          -  Participants chronically infected with hepatitis C virus (HCV) Genotype 1, 2, 3, 4, 5,
             or 6 with HCV RNA viral load of ≥10,000 IU/mL at screening

          -  Participants may be treatment-naïve or treatment-experienced

          -  Cirrhotic participants must have cirrhosis confirmed by biopsy, Fibroscan or fibrotest
             and Aspartate aminotransferase platelet ratio index (APRI) criteria as outlined in the
             protocol

          -  Post-transplant participants must be at least 3 months post-transplant with no
             evidence of moderate or severe rejection

        Exclusion Criteria:

          -  History of multi-organ transplant, with the exception of dual transplantation of the
             liver/kidney, is prohibited

          -  Current or known history of cancer (with the following exceptions: In situ carcinoma
             of the cervix, adequately treated basal or squamous cell carcinoma of the skin, or
             hepatocellular carcinoma within Milan criteria for transplantation) within 5 years
             prior to screening

          -  Evidence of an ongoing medical condition contributing to chronic liver disease other
             than HCV (such as, but not limited to: hemochromatosis, autoimmune hepatitis,
             metabolic liver disease, alcoholic liver disease, or toxin exposures)

          -  History of HIV infection or chronic hepatitis B virus (HBV) as documented by HBV
             serologies (e.g., HBsAg-seropositive). Participants with resolved HBV infection may
             participate (e.g., HBcAb-seropositive with concurrent HBsAg-seronegative)

          -  Active hospitalization for decompensated liver disease
Clinical trial NCT02032888 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, sofosbuvir
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Key Inclusion Criteria:

          -  Patients must be able to understand and agree to/comply with the prescribed dosing
             regimens and procedures, report for regularly scheduled study visits, and reliably
             communicate with study personnel about adverse events and concomitant medications

          -  Patients chronically infected with hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or
             6, as documented by positive HCV RNA at screening

          -  Patients who are HCV treatment-naive

          -  Patients who are HCV treatment-experienced and who have had prior anti-HCV therapies
             discontinued or completed at least 12 weeks prior to screening

          -  Patients with HCV RNA ≥10,000 IU/mL at screening

          -  Patients with HIV-1 infection

        Key Exclusion Criteria:

          -  Presence of AIDs-defining opportunistic infections, as defined by the Centers of
             Disease Control and Prevention, within 12 weeks prior to study entry

          -  Patients infected with HIV-2

          -  Liver or any other organ transplant (including hematopoietic stem cell transplants)
             other than cornea and hair

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to screening

          -  Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained
             imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this
             was performed

          -  Evidence of decompensated liver disease, including radiologic criteria, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy
Clinical trial NCT02032901 (phase 3, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: daclatasvir, sofosbuvir
SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Key Inclusion Criteria:

          -  Subjects must be able to understand and agree to comply with the prescribed dosing
             regimens and procedures, report for regularly scheduled study visits, and reliably
             communicate with study personnel about adverse events and concomitant medications

          -  Subjects chronically infected with hepatitis C virus (HCV) genotype 3

          -  Subjects who are HCV treatment-naive

          -  Subjects who are HCV treatment-experienced (previous exposure to non-structural 5A
             inhibitors is prohibited)

          -  HCV RNA ≥10,000 IU/mL at screening

        Key Exclusion Criteria:

          -  HCV Genotypes other than genotype-3 infection; mixed genotype infections are not
             permitted

          -  Liver or any other organ transplant (including hematopoietic stem cell transplants)
             other than cornea and hair

          -  Current or known history of cancer (except in situ carcinoma of the cervix or
             adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior
             to screening

          -  Documented or suspected hepatocellular carcinoma, as evidenced by previously obtained
             imaging studies or liver biopsy (or on a screening imaging study/liver biopsy if this
             was performed)

          -  Evidence of decompensated liver disease including, but not limited to, radiologic
             criteria, a history or presence of ascites, bleeding varices, or hepatic
             encephalopathy
Clinical trial NCT02034513 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin glargine, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria: - Subjects fulfilling at least one of the below criteria: a)
        Experienced at least one severe hypo episode within the last year (according to the ADA
        (American Diabetes Association) definition, April 2013) b) Moderate chronic renal failure,
        defined as glomerular filtration rate 30 - 59 mL/min/1.73 m^2 per CKD-Epi (chronic kidney
        disease epidemiology collaboration) c) Hypoglycaemic symptom unawareness d) Diabetes
        mellitus duration for more than 15 years e) Recent episode of hypoglycaemia (defined by
        symptoms of hypoglycaemia and/or episode with low glucose measurement (below or equal to 70
        mg/dL [below or equal to 3.9 mmol/L])) within the last 12 weeks prior to Visit 1
        (screening) - Male or female, age at least 18 years at the time of signing informed consent
        - Type 1 diabetes mellitus (diagnosed clinically) for at least 52 weeks prior to Visit 1 -
        Current treatment with a basal-bolus regimen consisting of neutral protamine Hagedorn (NPH)
        insulin OD (once daily) / BID (twice daily) or insulin detemir (IDet) OD / BID plus 2-4
        daily injections of any rapid acting meal time insulin or CSII (with rapid acting insulin)
        for at least 26 weeks prior to Visit 1 - HbA1c (glycosylated haemoglobin) below or equal to
        10% by central laboratory analysis - BMI (body mass index) below or equal to 45 kg/m^2
        Exclusion Criteria: - Treatment with IGlar or IDeg within the last 26 weeks prior to Visit
        1 (short term use [less than or equal to 2 weeks] is allowed, but not within 4 weeks prior
        to screening) - Use of any other anti-diabetic agent than those stated in the inclusion
        criteria within the last 26 weeks prior to Visit 1
Clinical trial NCT02037503 (phase 3, status: recruiting)
Conditions: suicidal ideation, major depressive disorder, healthy participants
ICD codes: R45.851, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: ketamine, saline
SMILES: CC1=CC(O)=CC(C)=C1Cl, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

        Suicidal Ideation group:

          1. Any person admitted to the emergency room department after a suicide attempt , defined
             as requiring medical intervention - not just a psychiatrist ( surgical or
             pharmacological treatment but also the need for observation ) .

          2. The need for medical intervention will be defined by the ER ED physician

          3. Ages 18-65

        For the depression group:

          1. Diagnosed with major depression according to DSM VI.

          2. Ongoing depression (according to DSM criteria) despite treatment with at least two
             antidepressants in adequate dosages and for longer than three weeks.

          3. Ages 18-65

        For the romantic relationship breakup:

        1. Participants that have experienced a meaningful romantic relationship break-up within
        the past 12 months

        -

        Exclusion Criteria for all groups:

          1. Psychotic state instate in the examination

          2. Diagnosis of schizophrenia / schizoaffective disorder

          3. Drug or alcohol abuse as is revealed in by blood/urine tests

          4. Patient in which, according to the examiner, there is primary or secondary gain.

          5. Patient , which, at the time of his admission , is without any pharmacological
             treatment.
Clinical trial NCT02038036 (phase 3, status: completed)
Conditions: polycythemia vera
ICD codes: D45
Drugs: best available therapy, ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Eligibility criteria:

        Inclusion Criteria:

        Confirmed diagnosis of PV according to the 2008 World Health Organization criteria,
        Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea, ECOG
        performance status of 0, 1 or 2.

        Exclusion Criteria:

        Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral
        infection requiring treatment, Active malignancy within the past 5 years, excluding
        specific skin cancers, Previously received treatment with a JAK inhibitor, Being treated
        with any investigational agent, Women who are pregnant or nursing.

        Other inclusion/exclusion criteria apply.
Clinical trial NCT02041533 (phase 3, status: active, not recruiting)
Conditions: stage iv or recurrent non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, cisplatin, carboplatin, paclitaxel, pemetrexed
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 1

          -  Histologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic
             anticancer therapy

          -  Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per
             response evaluation criteria in solid tumors version (RECIST) 1.1 criteria

          -  PD-L1+ on immunohistochemistry testing performed by central lab

          -  Men and women, ages ≥ 18 years of age

        Exclusion Criteria:

          -  Known epidermal growth factor receptor (EGFR) mutations which are sensitive to
             available targeted inhibitor therapy

          -  Known anaplastic lymphoma kinase (ALK) translocations

          -  Untreated central nervous system (CNS) metastases

          -  Previous malignancies

          -  Active, known or suspected autoimmune disease
Clinical trial NCT02042690 (phase 3, status: completed)
Conditions: acute lymphoblastic leukemia
ICD codes: C91.01, C91.02, C91.00
Drugs: chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  acute lymphoblastic leukemia

          -  18-39 years old

          -  in first complete remission -Adequate hepatic function defined as: total bilirubin
             ≤2.0 times the institutional upper limit of normal (ULN); alanine aminotransferase
             (ALT) and aspartate aminotransferase(AST) ≤2.5 times the institutional ULN -

          -  Adequate renal function defined as creatinine ≤3 times the institutional ULN

          -  No uncontrollable infection

          -  Performance Status(PS)score 0-2(WHO)

          -  Subjects able to provide written informed consent

        Exclusion Criteria:

          -  having HLA-matched donor

          -  high-risk ALL: (1)Ph+ALL (2)Hypodiploidy (3)t(v;11q23) (4) complex karyotype（≥5
             chromosome abnormalities）（5）high white blood cell (WBC) count (B-ALL≥30×109/L;T-ALL
             ≥100×109/L).

          -  pregnancy

          -  Loss of ability to freely provide consent due to psychiatric or physical illness